Combination of Capecitabine and GTI-2040 in the Treatment of Renal Cell Carcinoma
Public ClinicalTrials.gov record NCT00056173. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase I/II Study of GTI-2040 and Capecitabine Combination Therapy in Patients With Advanced or Metastatic Renal Cell Carcinoma (mRCC)
Study identification
- NCT ID
- NCT00056173
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Aptose Biosciences Inc.
- Industry
- Enrollment
- 43 participants
Conditions and interventions
Conditions
Interventions
- GTI-2040 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 28, 2002
- Primary completion
- Nov 30, 2004
- Completion
- Not listed
- Last update posted
- Jan 6, 2008
Started 2002
United States locations
- U.S. sites
- 10
- U.S. states
- 8
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Bay Area Cancer Research Group | Concord | California | 94520 | — |
| USC-Norris Comprehensive Cancer Center and Hospital | Los Angeles | California | 90033 | — |
| CA Hematology Oncology Medical Group | Torrance | California | 90505 | — |
| Innovative Medical Research of South Florida, Inc. | Miami Shores | Florida | 33138 | — |
| University of Chicago Medical Center | Chicago | Illinois | 60637 | — |
| Ochsner Clinic Foundation | New Orleans | Louisiana | 70121 | — |
| SUNY Upstate Medical University | Syracuse | New York | 13210 | — |
| Comprehensive Cancer Center of Wake Forest University | Winston-Salem | North Carolina | 27157-1082 | — |
| The Cleveland Clinic Foundation | Cleveland | Ohio | 44195 | — |
| Fox Chase Cancer Center | Philadelphia | Pennsylvania | 19111 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00056173, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 6, 2008 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00056173 live on ClinicalTrials.gov.